EQH Stock Analysis: Axa Equitable Holdings | NYSE
Asset Management | NYSE, USA | Market Cap: 14.358m USD | 12M Return: 9.9% | US29452E1010 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 160M
EPS Trend: 82.8%
Qual. Beats: 0
Rev. Trend: 26.2%
Qual. Beats: -1
Warnings
Tailwinds
Seasonality 8.4 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Equitable Holdings, Inc. (EQH) is a diversified financial services company that operates through six segments: Individual Retirement, Group Retirement, Asset Management, Protection Solutions, Wealth Management, and Legacy. The company provides variable annuity products, retirement plan services, investment management, life insurance, employee benefits, and wealth advisory services, serving clients ranging from individual retail and high-net-worth investors to institutions, small and medium-sized businesses, and tax-exempt entities. The Legacy segment includes capital-intensive fixed-rate guaranteed minimum withdrawal benefit (GMxB) business. Founded in 1859 and headquartered in New York, the company is the result of AXAs U.S. operations and rebranded from AXA Equitable Holdings to Equitable Holdings in January 2020.
Within the GICS Diversified Financial Services sub-industry, EQH operates across multiple insurance and asset management verticals, including variable annuities, life insurance, and institutional investment management. The Diversified Financial Services sub-industry generally includes companies with business lines spanning insurance, asset management, and capital markets activities, often generating revenue through premium income, asset-based fees, and advisory charges.
- Variable annuity sales fuel Individual Retirement fee growth
- Net investment income tracks Federal Reserve rate path
- Legacy GMxB runoff frees capital and reduces hedge costs
- Asset management fees swing with equity market levels
| Net Income: -926.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.00 > 0.02 and ΔFCF/TA -0.08 > 1.0 |
| NWC/Revenue: -909.0% < 20% (prev -506.9%; Δ -402.0% < -1%) |
| CFO/TA 0.00 > 3% & CFO 1.43b > Net Income -926.0m |
| Current Ratio: 0.30 > 1.5 & < 3 |
| Outstanding Shares: last quarter (278.3m) vs 12m ago -8.21% < -2% |
| Gross Margin: 72.67% > 18% (prev 66.96%; Δ 5.71% > 0.5%) |
| Asset Turnover: 3.33% > 50% (prev 4.24%; Δ -0.92% > 0%) |
| Interest Coverage Ratio: -1.70 > 6 (EBIT TTM -384.0m / Interest Expense TTM 226.0m) |
| A: -0.29 (Total Current Assets 40.4b - Total Current Liabilities 137b) / Total Assets 335b |
| B: 0.02 (Retained Earnings 8.23b / Total Assets 335b) |
| C: -0.00 (EBIT TTM -384.0m / Avg Total Assets 319b) |
| D: -0.00 (Book Value of Equity -785.0m / Total Liabilities 333b) |
| Altman-Z'' = -1.82 = D |
| DSRI: 2.50 (Receivables 23.0b/11.2b, Revenue 10.6b/12.9b) |
| GMI: 0.92 (GM 66.96% / 72.67%) |
| AQI: 1.11 (AQ_t 0.88 / AQ_t-1 0.79) |
| SGI: 0.83 (Revenue 10.6b / 12.9b) |
| TATA: -0.01 (NI -926.0m - CFO 1.43b) / TA 335b) |
| Beneish M = -1.93 (Cap -4..+1) = B |
As of October 07, 2026, the stock is trading at USD 54.50 with a total of 1,598,881 shares traded. Over the past week, the price has changed by +4.43%, over one month by +4.73%, over three months by +15.51% and over the past year by +9.88%.
Current recommended Stop Loss: 52.50 (which is 3.7% or 1.4 ATR below the current price).
Axa Equitable Holdings has received a consensus analysts rating of 4.67. Therefore, it is recommended to buy EQH.
- StrongBuy: 9
- Buy: 2
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 62.1 | 13.9% |
P/E Forward = 5.8173
P/S = 1.352
P/B = 164.1395
Revenue TTM = 10.6b USD
EBIT TTM = -384.0m USD
EBITDA TTM = 493.0m USD
Long Term Debt = 6.97b USD (from longTermDebt, last quarter)
Short Term Debt = 201.0m USD (from shortTermDebt, last quarter)
Debt = 7.17b USD (corrected: LT Debt 6.97b + ST Debt 201.0m)
Net Debt = -51.4b USD (calculated: Debt 7.17b - CCE 58.6b)
Enterprise Value = 14.4b USD (floored to Market Cap, CCE > MCap+Debt)
Interest Coverage Ratio = -1.70 (Ebit TTM -384.0m / Interest Expense TTM 226.0m)
EV/FCF = 10.29x (Enterprise Value 14.4b / FCF TTM 1.40b)
FCF Yield = 9.72% (FCF TTM 1.40b / Enterprise Value 14.4b)
FCF Margin = 13.14% (FCF TTM 1.40b / Revenue TTM 10.6b)
Net Margin = -8.72% (Net Income TTM -926.0m / Revenue TTM 10.6b)
Gross Margin = 72.67% ((Revenue TTM 10.6b - Cost of Revenue TTM 2.90b) / Revenue TTM)
Gross Margin QoQ = 74.67% (prev 90.69%)
Tobins Q-Ratio = 0.04 (Enterprise Value 14.4b / Total Assets 335b)
Interest Expense / Debt = 3.15% (Interest Expense 226.0m / Debt 7.17b)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -303.4m (EBIT -384.0m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 0.30 (Total Current Assets 40.4b / Total Current Liabilities 137b)
Debt / Equity = -9.13 (negative equity) (Debt 7.17b / totalStockholderEquity, last quarter -785.0m)
Debt / EBITDA = -104.3 (out of range, set to none) (Net Debt -51.4b / EBITDA 493.0m)
Debt / FCF = -36.87 (Net Debt -51.4b / FCF TTM 1.40b)
Total Stockholder Equity = -109.5m (last 4 quarters mean from totalStockholderEquity)
RoA = -0.29% (Net Income -926.0m / Total Assets 335b)
RoE = 845.7% (negative equity) (Net Income TTM -926.0m / Total Stockholder Equity -109.5m)
RoCE = -5.60% (EBIT -384.0m / Capital Employed (Equity -109.5m + L.T.Debt 6.97b))
RoIC = -0.09% (negative operating profit) (NOPAT -303.4m / Invested Capital 330b)
WACC = 7.49% (E(14.4b)/V(21.5b) * Re(9.99%) + D(7.17b)/V(21.5b) * Rd(3.15%) * (1-Tc(0.21)))
Discount Rate = 9.99% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -98.99 | Cagr: -7.63%
[DCF] Terminal Value 74.49% ; FCFF base≈1.43b ; Y1≈1.36b ; Y5≈1.29b
[DCF] Fair Price = 262.8 (EV 20.2b - Net Debt -51.4b = Equity 71.7b / Shares 272.8m; r=8.35% [WACC [floored]]; 5y FCF grow -6.63% → 2.50% )
EPS Correlation: 82.76 | EPS CAGR: 10.74% | SUE: 0.44 | # QB: 0
Revenue Correlation: 26.24 | Revenue CAGR: 2.78% | SUE: -1.48 | # QB: -1
EPS current Quarter (2026-09-30): EPS=1.89 | Chg30d=+0.28% | Revisions=+22% | Analysts=12
EPS current Year (2026-12-31): EPS=7.17 | Chg30d=+0.04% | Revisions=+8% | GrowthEPS=+27.1% | GrowthRev=+32.6%
EPS next Year (2027-12-31): EPS=9.01 | Chg30d=+0.00% | Revisions=+62% | GrowthEPS=+25.7% | GrowthRev=+11.5%
[Analyst] Revisions Ratio: +39% (up=18, down=7)